The Oxford Covid-19 vaccine supported by AstraZeneca (NYSE: AZN) it’s generating the kind of antibody and T-cell (killer cell) response that researchers would expect to see, reports Robert Peston, saying the first data will be published soon in The lancet.
That said, efficacy will only be adequately established in the large phase III program that is underway in the viral epicenter of Brazil, to deliver a large database that assesses safety and efficacy. As I understand it, not all vaccines in development around the world raise both antibodies and T cells. But the Oxford vaccine appears to have this twin effect. If proven effective, it could go into mass production in early September. “
Modern jumped 17% after the closing bell on Tuesday after the company released data showing that its potential coronavirus vaccine produces a “robust” immune response in all 45 patients in its early human trial.
The names of coronavirus vaccines are moving in the latest news in the premarket trade: AstraZeneca (AZN) + 3.6%; Pfizer (NYSE: PFE) + 1.3%, BioNTech (NASDAQ: BNTX) + 4.9%. Novavax (NASDAQ: NVAX) and Inovio Pharmaceuticals (NASDAQ: INO) They have not changed.
